# Study of CD388 Intramuscular or Subcutaneous Administration in Healthy Subjects

> **NCT05285137** · PHASE1 · COMPLETED · sponsor: **Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 77 (actual)

## Conditions studied

- Healthy

## Interventions

- **COMBINATION_PRODUCT:** CD388 Injection
- **DRUG:** Saline placebo

## Key facts

- **NCT ID:** NCT05285137
- **Lead sponsor:** Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-14
- **Primary completion:** 2023-10-27
- **Final completion:** 2023-10-27
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2025-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05285137

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05285137, "Study of CD388 Intramuscular or Subcutaneous Administration in Healthy Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05285137. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*